⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer

Official Title: A Randomized Controlled Study of Docetaxel Monotherapy or Docetaxel and DOXIL for the Treatment of Advanced Breast Cancer

Study ID: NCT00091442

Conditions

Breast Cancer

Interventions

Docetaxel
DOXIL

Study Description

Brief Summary: The purpose of the study is to evaluate whether the time to progression for the DOXIL and docetaxel combination therapy group was superior to that of the group treated with docetaxel monotherapy in participants with advanced breast cancer.

Detailed Description: This is a randomized (the study medication is assigned by a random order), active control (study medication will be compared with available standard care of treatment), parallel-group (each treatment group will be treated simultaneously at the same time and each participant only receives one treatment regimen as assigned), open-label (both the investigator and the participant know the intervention received by the participant), multicenter study designed to determine if women with locally advanced or metastatic breast cancer, who were previously treated with prior anthracycline therapy in the neoadjuvant (administration of treatment before surgery) or adjuvant setting (administration of treatment after surgery), and who also had a disease-free interval of at least 12 months since the end of their last cytotoxic therapy, would benefit from the addition of DOXIL to docetaxel therapy. Approximately 751 participants will be randomly assigned to either receive docetaxel monotherapy or DOXIL in combination with docetaxel therapy. Treatment is to continue until disease progression or the occurrence of unacceptable treatment related toxicity. Safety evaluations will include assessments of adverse events which will be recorded from the first study related procedure until 30 days after the last dose of medication; clinical laboratory tests and tests for cardiac function (multiple gated acquisition scan/echocardiogram and electrocardiogram) which will be monitored throughout the study.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: FEMALE

Healthy Volunteers: No

Locations

, Hoover, Alabama, United States

, Fountain Valley, California, United States

, Long Beach, California, United States

, Los Angeles, California, United States

, Palm Springs, California, United States

, Newark, Delaware, United States

, Lakeland, Florida, United States

, Fort Gordon, Georgia, United States

, Centralia, Illinois, United States

, Joliet, Illinois, United States

, Indianapolis, Indiana, United States

, Lexington, Kentucky, United States

, Louisville, Kentucky, United States

, Lafayette, Louisiana, United States

, Baltimore, Maryland, United States

, Jackson, Mississippi, United States

, Las Vegas, Nevada, United States

, Newark, New Jersey, United States

, Albuquerque, New Mexico, United States

, Bronx, New York, United States

, Cooperstown, New York, United States

, New York, New York, United States

, Gastonia, North Carolina, United States

, Philadelphia, Pennsylvania, United States

, Upland, Pennsylvania, United States

, Providence, Rhode Island, United States

, Charleston, South Carolina, United States

, N Charleston, South Carolina, United States

, Fort Worth, Texas, United States

, Pasadena, Texas, United States

, Plovdiv, , Bulgaria

, Shumen, , Bulgaria

, Sofia, , Bulgaria

, Stara Zagora, , Bulgaria

, Varna, , Bulgaria

, Tartu N/A, , Estonia

, Rabat, , France

, Tunis, , France

, Budapest N/A, , Hungary

, Budapest, , Hungary

, Debrecen, , Hungary

, Szeged, , Hungary

, Szekesfehervar, , Hungary

, Zalaegerszeg, , Hungary

, Ashkelon, , Israel

, Haifa, , Israel

, Jerusalem, , Israel

, Ramat-Gan, , Israel

, Tel Aviv, , Israel

, Riga, , Latvia

, Kaunas, , Lithuania

, Vilnius, , Lithuania

, Arnhem, , Netherlands

, Capelle Aan Den Ijssel, , Netherlands

, Den Haag, , Netherlands

, Roosendaal, , Netherlands

, Bialystok, , Poland

, Bydgoszcz, , Poland

, Bytom, , Poland

, Gdansk, , Poland

, Gdynia N/A, , Poland

, Gliwice, , Poland

, Kielce, , Poland

, Koszalin, , Poland

, Krakow, , Poland

, Lodz, , Poland

, Lublin, , Poland

, Olsztyn, , Poland

, Poznan, , Poland

, Warsaw, , Poland

, Coimbra, , Portugal

, Matosinhos N/A, , Portugal

, Bacau, , Romania

, Bucuresti, , Romania

, Cluj-Napoca, , Romania

, Hunedoara, , Romania

, Iasi, , Romania

, Onesti, , Romania

, Timisoara, , Romania

, Arkhangelsk, , Russian Federation

, Balashikha, , Russian Federation

, Barnaul, , Russian Federation

, Chelyabinsk, , Russian Federation

, Ekaterinburg, , Russian Federation

, Engels Saratov Region, , Russian Federation

, Irkutsk, , Russian Federation

, Ivanovo, , Russian Federation

, Izhevsk, , Russian Federation

, Kazan, , Russian Federation

, Krasnodar, , Russian Federation

, Leningrad Region, , Russian Federation

, Lipetsk, , Russian Federation

, Moscow N/A, , Russian Federation

, Moscow Region, , Russian Federation

, Moscow, , Russian Federation

, Murmansk, , Russian Federation

, N Novgorod N/A, , Russian Federation

, Nizhny Novgorod, , Russian Federation

, Novosibirsk, , Russian Federation

, Obninsk, , Russian Federation

, Omsk, , Russian Federation

, Orel, , Russian Federation

, Petrozavodsk, , Russian Federation

, Pyatigorsk, , Russian Federation

, Rostov-Na-Donu, , Russian Federation

, Ryazan, , Russian Federation

, Samara N/A, , Russian Federation

, Smolensk, , Russian Federation

, St Petersburg N/A, , Russian Federation

, St. Petersburg, , Russian Federation

, Stavropol, , Russian Federation

, Tomsk, , Russian Federation

, Tver, , Russian Federation

, Ulianovsk, , Russian Federation

, Vladimir, , Russian Federation

, Volgograd, , Russian Federation

, Voronezh, , Russian Federation

, Yaroslavl, , Russian Federation

, Beograd, , Serbia

, Nis, , Serbia

, Sremska Kamenica, , Serbia

, Cape Town, , South Africa

, Johannesburg, , South Africa

, Kimberley, , South Africa

, Parktown, , South Africa

, Port Elizabeth, , South Africa

, Pretoria Gauteng, , South Africa

, Pretoria, , South Africa

, Bilbao Vizcaya, , Spain

, Lérida, , Spain

, Madrid, , Spain

, Santander N/A, , Spain

, Sevilla, , Spain

, Cherkassy, , Ukraine

, Chernivtsi, , Ukraine

, Dnepropetrovsk, , Ukraine

, Donetsk, , Ukraine

, Kharkov, , Ukraine

, Kiev, , Ukraine

, Lugansk, , Ukraine

, Lutsk, , Ukraine

, Odessa, , Ukraine

, Poltava, , Ukraine

, Simferopol, , Ukraine

, Uzhgorod, , Ukraine

, Vinnitsa, , Ukraine

, Zhitomir, , Ukraine

, Huddersfield, , United Kingdom

, Manchester, , United Kingdom

, Nottingham, , United Kingdom

, Sutton, , United Kingdom

Contact Details

Name: Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial

Affiliation: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: